Hypoglycaemic and hypoketonaemic effects of single and repeated oral doses of @entity51139 ( @entity51139 ) in @entity3839 / @entity10835 -induced XXXX @entity235 .

@entity844 @entity6 @entity10835 @entity235 @entity3839 @entity51139 @entity16623 @entity6178 @entity413
1. The hypoglycaemic and hypoketonaemic effects of orally administered @entity51139 were studied in @entity3839 / @entity10835 -induced @entity6 @entity235 . 2. Single oral 50 mg doses (approximately 7.5 mg kg-1) of @entity51139 produced statistically significant reductions of plasma @entity413 (32 +/- 6% maximum reduction from baseline) and @entity16623 (74 +/- 12% maximum reduction from baseline), with the peak effect on plasma @entity16623 (3.5 h) preceding that for plasma @entity413 (6.0 h). 3. Lower doses (0.7-2.0 mg kg-1 daily) of @entity51139 given repeatedly for seven days produced reductions of blood @entity413 and @entity16623 equivalent to those produced with the higher single dose. Maximal reductions of plasma @entity16623 were generally observed following the first dose of drug, whereas significant lowering of plasma @entity413 required several days of continuous dosing. 4. Repeated daily doses of @entity51139 markedly reduced the overnight fasting @entity6178 levels but not @entity413 levels of @entity6 @entity235 . 5. In conclusion, administration of the @entity844 oxidation inhibitor @entity51139 , in the absence of concomitant insulin therapy, was able to lower the plasma @entity413 and @entity6178 levels of insulin-deficient @entity3839 / @entity10835 @entity6 @entity235 . Only the plasma @entity16623 were decreased to normal by this treatment.
